Latest

Express Scripts wants cancer drugs to prove value

Express Scripts wants cancer drugs to prove value

The pharmacy benefits manager wants oncology treatments priced according to how well they treat a specific cancer as opposed to using the current one-price-fits-all approach.

Roche diagnostic unit partnering with drugmaker on companion diagnostic

The test seeks to identify patients with metastatic pancreatic cancer and high levels of hyaluronan.

New bill seeks to spur FDA to form clearer social media rules

New bill seeks to spur FDA to form clearer social media rules

Rep. Billy Long introduced legislation that is meant to push the FDA to implement clearer guidelines for regulating drug product information on social media.

Five things for pharma marketers to know: Wednesday, May 27

Five things for pharma marketers to know: Wednesday, May 27

Express Scripts seeks to pay more for top-performing cancer drugs; Olympus plans to settle marketing investigation; Novartis is collaborating on a robotic pill

Med-Tech Marketing: Wearables and Beyond

Med-Tech Marketing: Wearables and Beyond

Long considered one of the staid, self-contained areas of the healthcare biz, the device/diagnostics space has enjoyed an injection of energy as the potential for integration with mobile devices has become more obvious. But are these companies set up to work alongside their traditional pharma partners, much less the entrepreneurial-minded start-ups that aim to reinvent the category? Larry Dobrow surveys the opportunities and frustrations

NPs expand right to practice independently

Twenty states now allow nurse practitioners to practice without an MD affiliation.

ASCO preview: What's coming for lung cancer

ASCO preview: What's coming for lung cancer

A horse race between Merck and Bristol-Myers Squibb, and the importance of one biomarker, will be a focus at the American Society of Clinical Oncology's annual meeting.

Court orders Actavis to keep Namenda IR on market

An appeals court affirmed an earlier ruling that Actavis must keep an older formulation of its Alzheimer's drug, Namenda, on the market.

J&J puts global media business up for review

J&J puts global media business up for review

The review does not include North America, the healthcare giant said.

Five things for pharma marketers to know: Tuesday, May 26

Five things for pharma marketers to know: Tuesday, May 26

Experimental psoriasis drug linked to suicidal thoughts; analysis finds that some high prescribers receive non-research industry money; researchers say new MS drugs spur higher prices of older medications

Novo Nordisk executive fuels firm's new obesity fight

Novo Nordisk executive fuels firm's new obesity fight

"An epidemic comes and goes. This is a trend curve. We need to bend that curve."

Five things for pharma marketers to know: Friday, May 22

Five things for pharma marketers to know: Friday, May 22

Amgen's PSCK9 inhibitor gets a position opinion in the EU; the FDA plans to study how spouses influence perception of DTC ads; Botox may relieve depression

Pharma and Self-Perception: Knights, Knaves or Pawns?

Pharma and Self-Perception: Knights, Knaves or Pawns?

Even the industry's sunniest personalities don't deny that pharma has an image problem among outside constituencies, with an unfortunately high percentage of observers believing the biz is first and foremost about profits. Sachin Jain dives deep on this and other perceptions—accurate and otherwise—about the industry and its marketing machinery

Pharmanormal activities

Pharmanormal activities

When Monique Levy, one of the most-level-headed analysts in the pharma industry, calls attention to a mysterious phenomenon, you listen.

21st Century Cures bill advances to House floor

21st Century Cures bill advances to House floor

The legislation would allow drugmakers to share economic information with payers beyond what is included on the FDA-approved label.

Agency Spotlight



Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.

Email Newsletters